Monoclonal antibodies that block PD1 or PDL1 are among the most-promising immunotherapies available in advanced cancers, including pembrolizumab and nivolumab for melanoma and non-small-cell lung cancer (NSCLC) [1–5]. Adverse events related to anticancer immunotherapy have been extensively investigated; we report the first case, to our knowledge, of cryoglobulinemia associated with the use of anti-PD-1 antibody, nivolumab, in patient affected by advanced NSCLC.
Pellegrino, B., Musolino, A., Tiseo, M. (2017). Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. ANNALS OF ONCOLOGY, 28(6), 1405-1406 [10.1093/annonc/mdx126].
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient
Musolino, A.
;
2017
Abstract
Monoclonal antibodies that block PD1 or PDL1 are among the most-promising immunotherapies available in advanced cancers, including pembrolizumab and nivolumab for melanoma and non-small-cell lung cancer (NSCLC) [1–5]. Adverse events related to anticancer immunotherapy have been extensively investigated; we report the first case, to our knowledge, of cryoglobulinemia associated with the use of anti-PD-1 antibody, nivolumab, in patient affected by advanced NSCLC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
